Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 1.9% - Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price rose 1.9% during trading on Wednesday . The stock traded as high as $38.75 and last traded at $38.44. Approximately 173,439 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 1,362,350 shares. The stock had previously closed at $37.74.

Analyst Ratings Changes

TNXP has been the subject of several analyst reports. Noble Financial reissued an "outperform" rating and issued a $70.00 price objective on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Alliance Global Partners reissued a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd.

Tonix Pharmaceuticals Trading Down 7.4%

The stock has a market capitalization of $234.25 million, a PE ratio of -0.01 and a beta of 2.09. The firm has a 50 day moving average price of $25.07 and a 200 day moving average price of $23.59. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.23) by $0.39. The company had revenue of $2.43 million during the quarter, compared to analyst estimates of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 4,000 shares of Tonix Pharmaceuticals stock in a transaction dated Thursday, May 15th. The stock was bought at an average cost of $21.55 per share, with a total value of $86,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,005 shares in the company, valued at approximately $86,307.75. The trade was a 80,000.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.03% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after acquiring an additional 1,855,907 shares in the last quarter. Jane Street Group LLC grew its holdings in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Point72 Asset Management L.P. bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at $526,000. Northern Trust Corp bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at $162,000. Finally, Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at $66,000. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.